Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Gross Profit (2016 - 2025)

Ani Pharmaceuticals' Gross Profit history spans 14 years, with the latest figure at $146.8 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 33.09% year-over-year to $146.8 million; the TTM value through Dec 2025 reached $542.1 million, up 48.85%, while the annual FY2025 figure was $542.1 million, 48.85% up from the prior year.
  • Gross Profit for Q4 2025 was $146.8 million at Ani Pharmaceuticals, up from $134.4 million in the prior quarter.
  • Across five years, Gross Profit topped out at $146.8 million in Q4 2025 and bottomed at -$8.8 million in Q1 2021.
  • The 5-year median for Gross Profit is $76.2 million (2023), against an average of $73.1 million.
  • The largest annual shift saw Gross Profit crashed 131.41% in 2021 before it soared 443.84% in 2022.
  • A 5-year view of Gross Profit shows it stood at $27.0 million in 2021, then surged by 114.22% to $57.9 million in 2022, then surged by 35.11% to $78.2 million in 2023, then soared by 40.98% to $110.3 million in 2024, then surged by 33.09% to $146.8 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Gross Profit are $146.8 million (Q4 2025), $134.4 million (Q3 2025), and $136.8 million (Q2 2025).